Kintor Pharmaceutical Ltd. (“Kintor Pharma”) has released its circular for the Annual General Meeting (AGM) scheduled for 18 June 2026 in Suzhou, Jiangsu, detailing four key resolutions for shareholder approval.
Kintor Pharma will seek to: 1. Re-elect three retiring directors—Executive Director Dr Xiang Ni and Non-executive Directors Mr Yunfei Chen and Ms Geqi Wei—after a positive performance assessment by the Nomination Committee. 2. Appoint Rongcheng (Hong Kong) CPA Limited as external auditor for the 2026 financial year, replacing PricewaterhouseCoopers, whose tenure ends at the AGM. The proposed audit fee is approximately RMB1.60 million, subject to finalisation. 3. Grant the Board a general mandate to issue, allot or transfer up to 20% of the company’s issued share capital (excluding treasury shares) as at the AGM date—equivalent to a maximum of 99.73 million new shares based on the current 498.66 million shares outstanding. 4. Authorise the company to repurchase up to 10% of its issued share capital—up to 49.87 million shares—and, conditional on approval, add the number of shares repurchased to the share-issuance mandate (Extension Mandate).
The proposed mandates will remain effective until the next AGM, the expiration of the statutory period for holding that meeting, or their earlier revocation. The Board states that the auditor rotation aims to strengthen corporate governance and maintain audit independence. No disagreements with the outgoing auditor, PwC, were reported.
The share register will close from 15–18 June 2026, and shareholders must lodge transfer documents by 12 June 2026 to qualify for AGM attendance and voting. All AGM resolutions will be decided by poll.
Comments